Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

• Published in: The Journal of clinical investigation Vol. 124; no. 2; pp. 509 - 514
• Main Authors: Merovci, Aurora, Solis-Herrera, Carolina, Daniele, Giuseppe, Eldor, Roy, Fiorentino, Teresa Vanessa, Tripathy, Devjit, Xiong, Juan, Perez, Zandra, Norton, Luke, Abdul-Ghani, Muhammad A., DeFronzo, Ralph A.
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 01.02.2014
• Subjects: Benzhydryl Compounds; Biomedical research; Blood Glucose - metabolism; Body Weight; Complications and side effects; Dapagliflozin; Diabetes Mellitus, Type 2 - drug therapy; Dosage and administration; Drug therapy; Fasting; Glucagon - blood; Glucose; Glucose - analysis; Glucose Clamp Technique; Glucose metabolism; Glucosides - therapeutic use; Humans; Hyperglycemia; Hyperglycemia - metabolism; Insulin; Insulin - blood; Insulin - metabolism; Insulin resistance; Male; Metformin - administration & dosage; Middle Aged; Muscles - drug effects; Patient outcomes; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds - administration & dosage; Time Factors; Type 2 diabetes

Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated in animal models by inducing glucosuria with renal glucose transport inhibitors. Here, we examined whether reduction of plasma glucose with a sodium-glucose cotransporter 2 (SGLT2) inhibitor could impr...